发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment. 治疗转移性黑色素瘤的免疫检查点抑制剂诱发无菌性鼻窦炎。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-09-13 DOI: 10.1080/1750743x.2024.2399498
Sofia Tzoumpa,Béatrice Villette,Florence Granel-Brocard,Caroline Dutriaux,Alexandre Memmi,Geraldine Jeudy,Victor Tafani,Melanie Saint-Jean,Charlee Nardin,Elisa Funck-Brentan,Yannick Le Corre,Gaëlle Quereux,Eve Maubec
{"title":"Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment.","authors":"Sofia Tzoumpa,Béatrice Villette,Florence Granel-Brocard,Caroline Dutriaux,Alexandre Memmi,Geraldine Jeudy,Victor Tafani,Melanie Saint-Jean,Charlee Nardin,Elisa Funck-Brentan,Yannick Le Corre,Gaëlle Quereux,Eve Maubec","doi":"10.1080/1750743x.2024.2399498","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2399498","url":null,"abstract":"Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for melanoma treatment. Twelve patients were included (50% women, median age 58 years). Overall, the paraclinical assessment, the inefficacy of antibiotic/antihistaminic treatment, the improvement of symptoms on immunosuppressants and/or after ICI discontinuation, and the presence of multiple concomitant immune-related adverse-events, suggested a noninfectious etiology. Recognizing this toxicity is imperative for limitation of diagnostic wandering and appropriate treatment. However, additional epidemiological studies are needed to assess its prevalence as a potential immune-related adverse-event, and its prognostic value in patients treated with ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"14 1","pages":"1-9"},"PeriodicalIF":2.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142247524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combining immunotherapy with PARP inhibitors. Is it possible to find the way through? 将免疫疗法与 PARP 抑制剂相结合。有可能找到突破口吗？
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-09-13 DOI: 10.1080/1750743x.2024.2398412
Georgios I Papageorgiou,Nikolaos Skouteris,Kleopatra Eleftheriou,Christos Kosmas
{"title":"Combining immunotherapy with PARP inhibitors. Is it possible to find the way through?","authors":"Georgios I Papageorgiou,Nikolaos Skouteris,Kleopatra Eleftheriou,Christos Kosmas","doi":"10.1080/1750743x.2024.2398412","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2398412","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"8 1","pages":"1-5"},"PeriodicalIF":2.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142247523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. CD40 激动剂 MEDI5083 联合 durvalumab 治疗晚期实体瘤患者的 1 期研究。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-09-12 DOI: 10.1080/1750743x.2024.2359359
Ben Tran,Mark Voskoboynik,Johanna Bendell,Martin Gutierrez,Charlotte Lemech,Daphne Day,Sophia Frentzas,Ignacio Garrido-Laguna,Nathan Standifer,Fujun Wang,Charles Ferte,Yue Wang,Mayukh Das,Benedito A Carneiro
{"title":"A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.","authors":"Ben Tran,Mark Voskoboynik,Johanna Bendell,Martin Gutierrez,Charlotte Lemech,Daphne Day,Sophia Frentzas,Ignacio Garrido-Laguna,Nathan Standifer,Fujun Wang,Charles Ferte,Yue Wang,Mayukh Das,Benedito A Carneiro","doi":"10.1080/1750743x.2024.2359359","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2359359","url":null,"abstract":"Aim: This first-in-human study evaluated safety and efficacy of CD40 agonist MEDI5083 with durvalumab in patients with advanced solid tumors.Methods: Patients received MEDI5083 (3-7.5 mg subcutaneously every 2 weeks × 4 doses) and durvalumab (1500 mg every 4 weeks) either sequentially (N = 29) or concurrently (N = 9). Primary end point was safety; secondary end points included efficacy.Results: Thirty-eight patients received treatment. Most common adverse events (AEs) were injection-site reaction (ISR; sequential: 86%; concurrent: 100%), fatigue (41%; 33%), nausea (20.7%; 55.6%) and decreased appetite (24.1%; 33.3%). Nine patients had MEDI5083-related grade ≥3 AEs with ISR being the most common. Two patients experienced dose limiting toxicities (ISR). One death occurred due to a MEDI5083-related AE. MEDI5083 maximum tolerated dose was 5 mg. Objective response rate was 2.8% (1 partial response and 11 stable disease).Conclusion: MEDI5083 toxicity profile limits its further development.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"38 1","pages":"1-16"},"PeriodicalIF":2.8,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142247537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profiling of autoantibodies in the sera of glioblastoma patients. 分析胶质母细胞瘤患者血清中的自身抗体。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-09-12 DOI: 10.1080/1750743x.2024.2390350
Johannes Low Jun Wei,Ammar Akram Kamarudin,Soon Bee Hong,Kamalanathan Palaniandy,Azizi Abu Bakar,Jegan Thanabalan,Ramesh Kumar Athi Kumar,Ainul Syahrilfazli Jaafar,Sanmugarajah Paramasvaran,Farizal Fadzil,Nadiah Abu
{"title":"Profiling of autoantibodies in the sera of glioblastoma patients.","authors":"Johannes Low Jun Wei,Ammar Akram Kamarudin,Soon Bee Hong,Kamalanathan Palaniandy,Azizi Abu Bakar,Jegan Thanabalan,Ramesh Kumar Athi Kumar,Ainul Syahrilfazli Jaafar,Sanmugarajah Paramasvaran,Farizal Fadzil,Nadiah Abu","doi":"10.1080/1750743x.2024.2390350","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2390350","url":null,"abstract":"Aim: This study aimed to determine the expression pattern of autoantibody proteins from the serum of grade IV glioblastoma patients.Materials & methods: We performed high throughput antibody profiling via the Sengenics i-Ome® Protein Array to determine the differentially expressed autoantibodies.Results: The results portrayed that anti-COL4A3BP and anti-HSP90AA1 were among the upregulated autoantibodies in glioblastoma sera.Conclusion: The selected autoantibodies offer promising targets for future glioblastoma pathogenesis. However, further validation is required to elucidate the autoantibody signature in glioblastoma patients.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"42 1","pages":"1-8"},"PeriodicalIF":2.8,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142209395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case reports of immune-related cystitis and the antibody combination hypothesis. 免疫相关性膀胱炎病例报告与抗体组合假说。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-09-12 DOI: 10.1080/1750743x.2024.2389761
Peng Zhang,Chunyan Yin,Ming Yang
{"title":"Case reports of immune-related cystitis and the antibody combination hypothesis.","authors":"Peng Zhang,Chunyan Yin,Ming Yang","doi":"10.1080/1750743x.2024.2389761","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2389761","url":null,"abstract":"Immune-related cystitis is a rare condition, and its diagnostic criteria and pathogenesis are not yet fully understood. Here, we report two cases of immune-related cystitis. Both patients were previously diagnosed with lung squamous cell carcinoma and received combined treatment with immune checkpoint inhibitors and chemotherapy, leading to hemorrhagic cystitis. We reviewed the cystoscopic images and pathological features of previous cases and found that autoantibodies against hemidesmosomes may be the cause of immune-related cystitis, proposing the \"antibody combination\" hypothesis to explain the tissue specificity of the condition.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"11 1","pages":"1-9"},"PeriodicalIF":2.8,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142209396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity. 尼妥珠单抗加伊匹单抗辅助治疗期间的隐匿性检查点抑制剂心肌炎：一种隐匿但严重的毒性。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-09-11 DOI: 10.1080/1750743x.2024.2385286
Dimitrios Bafaloukos,Ioanna Gazouli,Aikaterini Bousmpoukea,Aristea Molfeta,Eleni Chatzichristou,George Samonis,Ioannis Vathiotis
{"title":"Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity.","authors":"Dimitrios Bafaloukos,Ioanna Gazouli,Aikaterini Bousmpoukea,Aristea Molfeta,Eleni Chatzichristou,George Samonis,Ioannis Vathiotis","doi":"10.1080/1750743x.2024.2385286","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2385286","url":null,"abstract":"Checkpoint inhibitor myocarditis is a rare but life-threatening toxicity of immunotherapy, occasionally manifesting as persistent troponin elevation. Dual checkpoint blockade with ipilimumab and nivolumab has been found to induce immune-related myocarditis in patients with metastatic melanoma. We herein report a case of smoldering immune-related myocarditis in a 54-year-old male after a single infusion of nivolumab plus ipilimumab as adjuvant treatment for completely resected stage IV melanoma. High-dose steroid treatment resulted in decrease in the levels of cardiac enzymes, without any major complications.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"19 1","pages":"1-6"},"PeriodicalIF":2.8,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142209411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Good response to cadonilimab as first-line treatment in superaged patient with advanced gastric cancer: a case report. 晚期胃癌超高龄患者对卡多尼单抗一线治疗的良好反应：病例报告。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-09-11 DOI: 10.1080/1750743x.2024.2394405
Jia Lun,Guikai Ma,Xuan Wang,Qian Wang
{"title":"Good response to cadonilimab as first-line treatment in superaged patient with advanced gastric cancer: a case report.","authors":"Jia Lun,Guikai Ma,Xuan Wang,Qian Wang","doi":"10.1080/1750743x.2024.2394405","DOIUrl":"https://doi.org/10.1080/1750743x.2024.2394405","url":null,"abstract":"Gastric cancer remains a considerable global health burden, with limited treatment options available for advanced cases, especially for superaged patients. Cadonilimab, a first-in-class bi-specific antibody (BsAb), offer a promising immunotherapy approach by targeting PD-1/CTLA-4 simultaneously. Herein, we present a case report of an 85-year-old patient with HER2-negative advanced gastric cancer who received first-line treatment with cadonilimab combined with chemotherapy, but cadonilimab was discontinued due to the observation of immune-related pneumonitis during treatment. Despite these changes, the patient still exhibited a stable disease condition for a year until now. This case report highlights the potential of cadonilimab in the treatment of superaged patients with advanced gastric cancer, while the efficacy and safety of it need to be further evaluated.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"06 1","pages":"1-5"},"PeriodicalIF":2.8,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142209412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab. 接受 nivolumab 治疗的转移性肾细胞癌患者既往 TKI 类型的预后价值。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-08-19 DOI: 10.1080/1750743X.2024.2385881
Alessandra Damassi, Malvina Cremante, Alessio Signori, Sara Elena Rebuzzi, Andrea Malgeri, Marilena Di Napoli, Orazio Caffo, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Veronica Prati, Marianna Tudini, Francesco Atzori, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Fabio Catalano, Veronica Murianni, Pasquale Rescigno, Giuseppe Luigi Banna, Giuseppe Fornarini, Sebastiano Buti
{"title":"Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.","authors":"Alessandra Damassi, Malvina Cremante, Alessio Signori, Sara Elena Rebuzzi, Andrea Malgeri, Marilena Di Napoli, Orazio Caffo, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Veronica Prati, Marianna Tudini, Francesco Atzori, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Fabio Catalano, Veronica Murianni, Pasquale Rescigno, Giuseppe Luigi Banna, Giuseppe Fornarini, Sebastiano Buti","doi":"10.1080/1750743X.2024.2385881","DOIUrl":"https://doi.org/10.1080/1750743X.2024.2385881","url":null,"abstract":"<p><p><b>Aim:</b> To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab.<b>Materials and methods:</b> A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs. pazopanib) and overall response rate (ORR), disease control rate, progression-free survival and overall survival were investigated. Additionally, the impact of TKI choice according to the International Metastatic RCC Database Consortium prognostic score was examined.<b>Results:</b> There was no significant difference between sunitinib and pazopanib groups in terms of mPFS, mOS, overall response rate and disease control rate. Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score.<b>Conclusion:</b> There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.7,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers? 免疫检查点抑制剂治疗转移性三阴性乳腺癌的前景如何？
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-04-30 DOI: 10.2217/imt-2024-0030
Ramon Andrade de Mello, Kátia Roque Perez, Puteri Abdul Haris
{"title":"What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?","authors":"Ramon Andrade de Mello, Kátia Roque Perez, Puteri Abdul Haris","doi":"10.2217/imt-2024-0030","DOIUrl":"https://doi.org/10.2217/imt-2024-0030","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease 利桑珠单抗在中重度克罗恩病治疗算法中的定位
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-04-17 DOI: 10.2217/imt-2023-0219
Francesca Lusetti, Ferdinando D'Amico, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Simona Radice, Laurent Peyrin-Biroulet, Silvio Danese
{"title":"Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease","authors":"Francesca Lusetti, Ferdinando D'Amico, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Simona Radice, Laurent Peyrin-Biroulet, Silvio Danese","doi":"10.2217/imt-2023-0219","DOIUrl":"https://doi.org/10.2217/imt-2023-0219","url":null,"abstract":"Risankizumab is a humanized monoclonal antibody that inhibits the p19 subunit of IL-23 cytokine. Recently it has been approved for the treatment of patients with moderate-to-severe Crohn's disease (CD). We conducted a scoping review to summarize the available data on risankizumab and to define its positioning in the treatment algorithm of CD. Pubmed, Embase and Scopus databases were searched up to Oct 31, 2023 to identify studies reporting efficacy and safety data of risankizumab in patients with CD. Risankizumab is an effective and safe drug for the management of patients with moderate-to-severe CD. It could be used as first-line therapy in biologic-naive patients and in patients who have previously failed other biological therapies.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"19 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140611963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信